自动荧光免疫分析系统与Roche Elecsys及Beckman Coulter Access 2抗苗勒管激素检测方法的比较
该研究依据CLSI指南评估了新型AFIAS AMH检测的分析性能,并用293份不孕门诊血清样本比较了AFIAS、Elecsys和Access 2三种AMH检测方法。结果显示AFIAS在0.420-72.386 pmol/L范围内线性良好,重复性CV为6.341%,三种方法间相关性很强。结论认为AFIAS AMH检测可作为Roche Elecsys和Beckman Coulter Access 2的替代方法。
要点
- AFIAS AMH检测在0.420-72.386 pmol/L范围内线性良好。
- AFIAS与Elecsys、Access 2的相关性均很强(Spearman's rho≥0.978)。
- AFIAS AMH检测或可作为Roche Elecsys和Beckman Coulter Access 2的替代方法。
核心结论
- AFIAS AMH检测可能作为Roche Elecsys和Beckman Coulter Access 2 AMH检测的替代方法。
研究设计与样本
- 依据CLSI EP05和EP06指南,使用人重组AMH样本评估AFIAS AMH检测的线性、重复性和实验室内精密度(CV%)。
- 依据CLSI EP09指南,使用293份不孕门诊血清样本比较AFIAS、Elecsys和Access 2三种AMH检测的AMH水平。
主要发现
- AFIAS AMH检测在0.420-72.386 pmol/L AMH的测量范围内呈线性,重复性为6.341%。
- AFIAS AMH检测在1.786、7.143和56.857 pmol/L三个浓度质控品的CV%分别为5.801%、5.714%和6.228%。
- AFIAS与Elecsys的斜率为1.055(95%CI 1.022-1.088),Spearman's rho为0.978(95%CI 0.973-0.983)。
- Elecsys与Access 2的斜率为0.813(95%CI 0.791-0.834),Spearman's rho为0.986(95%CI 0.983-0.989)。
- AFIAS与Access 2的斜率为0.836(95%CI 0.821-0.853),Spearman's rho为0.984(95%CI 0.980-0.988)。
关键数值与推荐
- AFIAS AMH检测的线性范围为0.420-72.386 pmol/L。
- AFIAS AMH检测的重复性为6.341%。
- AFIAS AMH检测在1.786、7.143和56.857 pmol/L三个浓度质控品的CV%分别为5.801%、5.714%和6.228%。
临床怎么用
- 在不孕症临床实践中,AFIAS AMH检测结果与Roche Elecsys和Beckman Coulter Access 2高度相关,可作为替代检测平台。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Since 2017, automated assays have been used in most clinical laboratories for anti-Müllerian hormone (AMH) level measurement. We evaluated the analytical performance of the newly developed automated fluorescent immunoassay system (AFIAS) AMH assay (Boditech Med, Gangwon-do, Korea) in comparison with the Roche Elecsys and Beckman Coulter Access 2 AMH assays. METHODS: Analytical performance of the AFIAS AMH assay was assessed in terms of linearity, repeatability, and within-laboratory precision (CV%) using human recombinant AMH samples according to the Clinical and Laboratory Standards Institute (CLSI) guidelines EP05 and EP06. Using 293 serum samples collected from an infertility clinic, the AMH levels were compared across AFIAS, Elecsys, and Access 2 AMH assays according to the CLSI EP09 guidelines. RESULTS: The AFIAS AMH assay results were linear across the measurement range of 0.420-72.386 pmol/L AMH, with repeatability of 6.341%. CV% of the AFIAS AMH assay for three levels of control, 1.786, 7.143, and 56.857 pmol/L, were 5.801%, 5.714%, and 6.228%, respectively. The results of the three AMH assays showed strong correlation: AFIAS and Elecsys [slope, 1.055 (95% confidence interval (CI), 1.022-1.088) and Spearman's rho, 0.978 (95% CI, 0.973-0.983)], Elecsys and Access 2 [slope, 0.813 (95% CI, 0.791-0.834) and Spearman's rho, 0.986 (95% CI, 0.983-0.989)], and AFIAS and Access 2 [slope, 0.836 (95% CI, 0.821-0.853) and Spearman's rho, 0.984 (95% CI, 0.980-0.988)]. CONCLUSIONS: The AFIAS AMH assay may be an alternative to the Roche Elecsys and Beckman Coulter Access 2 AMH assays.
引用
- Han A, Suh B, Yi G, et al. Comparison of the Automated Fluorescent Immunoassay System With Roche Elecsys and Beckman Coulter Access 2 Assays for Anti-Müllerian Hormone Measurement. Ann Lab Med. 2022. PMID: 34374348. doi:10.3343/alm.2022.42.1.47
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。